» Articles » PMID: 34593437

The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment

Overview
Journal Anticancer Res
Specialty Oncology
Date 2021 Oct 1
PMID 34593437
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aim: The limited efficacy of immune checkpoint inhibitors in colorectal cancer (CRC) is likely due to immunosuppressive mechanisms including T cell exhaustion caused by inhibitory immune checkpoints in the tumor microenvironment.

Materials And Methods: We investigated the expression status of the inhibitory immune checkpoint receptors on tumor-infiltrating T cells and their ligands on tumor cells by flow cytometry and immunohistochemistry, using surgically-resected specimens of CRC.

Results: Flow cytometry analysis indicated that TIM-3, TIGIT, and PD-1 were expressed on tumor-infiltrating CD4+ (8.3%, 56.0%, 26.1%) and CD8+ T cells (8.2%, 51.6%, 23.5%), and CRC cells abundantly expressed PD-L1, CEACAM-1, and CD155 (2.2%, 77.0%, 46.8%). Immunohistochemical analysis revealed that the tumor proportional score of PD-L1, CEACAM-1, and CD155 was 42.4%, 54.2%, and 52.1%, respectively.

Conclusion: PD-1, TIM-3, and TIGIT axes may reduce T cell function in the CRC tumor microenvironment.

Citing Articles

Effect of colorectal cancer stem cells on the development and metastasis of colorectal cancer.

Deng R, Zheng X, Lu Z, Yuan M, Meng Q, Wu T World J Gastrointest Oncol. 2024; 16(11):4354-4368.

PMID: 39554751 PMC: 11551631. DOI: 10.4251/wjgo.v16.i11.4354.


Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.

Zhang Y, Zhang C, Chen G, You H, Wang S, Wang X Transl Oncol. 2024; 46:102031.

PMID: 38861853 PMC: 11209639. DOI: 10.1016/j.tranon.2024.102031.


M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment.

Ito M, Mimura K, Nakajima S, Okayama H, Saito K, Nakajima T Cancer Immunol Immunother. 2023; 72(7):2233-2244.

PMID: 36869896 PMC: 10992489. DOI: 10.1007/s00262-023-03406-6.


Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy.

Ducoin K, Bilonda-Mutala L, Deleine C, Oger R, Duchalais E, Jouand N Cancers (Basel). 2022; 14(17).

PMID: 36077799 PMC: 9454990. DOI: 10.3390/cancers14174261.


Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients.

Xu Y, Cao C, Zhu Z, Wang Y, Tan Y, Xu X Front Genet. 2022; 13:901734.

PMID: 35734431 PMC: 9208084. DOI: 10.3389/fgene.2022.901734.